According to Fangsheng Pharmaceutical's announcement, the company has received the “Drug Registration Certificate” for adenosylcobalamin capsules approved and issued by the State Drug Administration. The drug is a class 3 chemical with a specification of 0.5 mg. The drug approval number is valid until October 12, 2031. The marketing license holder and manufacturer are all companies. Adenosylcobalamin capsules are suitable for conditions such as megaloblastic anemia and polyneuritis, and can also be used for adjuvant treatment of leukopenia. As of the announcement date, the drug project had invested a total of 3.2911 million yuan. This approval is conducive to enriching the company's product categories, and it is expected that it will not have a significant impact on the company's performance in the short term.

According to Fangsheng Pharmaceutical's announcement, the company has received the “Drug Registration Certificate” for adenosylcobalamin capsules approved and issued by the State Drug Administration. The drug is a class 3 chemical with a specification of 0.5 mg. The drug approval number is valid until October 12, 2031. The marketing license holder and manufacturer are all companies. Adenosylcobalamin capsules are suitable for conditions such as megaloblastic anemia and polyneuritis, and can also be used for adjuvant treatment of leukopenia. As of the announcement date, the drug project had invested a total of 3.2911 million yuan. This approval is conducive to enriching the company's product categories, and it is expected that it will not have a significant impact on the company's performance in the short term.